MRI boosts myocardial infarction assessment
Combining T2-weighted MRI to detect microvascular obstructions with delayed-enhancement imaging to measure tissue viability offers clinicians a better way to assess myocardial infarction, according to a new study from Japan.
Combining T2-weighted MRI to detect microvascular obstructions with delayed-enhancement imaging to measure tissue viability offers clinicians a better way to assess myocardial infarction, according to a new study from Japan.
“Non–contrast-enhanced MRI alone is not sufficient for accurate diagnosis of acute MI,” said principal investigator Dr. Yoko Mikami, a radiologist at Tsu City's Mie University Hospital.
Mikami and colleagues prospectively enrolled 37 patients diagnosed with acute myocardial infarction. Patients underwent a protocol including T2-weighted and late-enhanced MRI about five days after the onset of acute myocardial infarction. The investigators found that T2 imaging accurately pinned down areas of microvascular obstruction, which strongly correlate with post-MI hemorrhagic infarction.
The findings appeared in the October issue of the American Journal of Roentgenology.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
